|
End-of-day quote
Shanghai S.E.
2026-08-19
|
5-day change | 1st Jan Change | ||
| 71.20 CNY | -1.90% |
|
-4.39% | +4.60% |
| 08-11 | Gan & Lee Pharmaceuticals Grants Menarini Licensing Rights to Develop Diabetes Drug in Europe; Shares Jump 10% | MT |
| 07-13 | Gan & Lee Pharmaceuticals Gets China Nod for Breast Cancer Drug Trial | MT |
| Market Cap | 42.38B 6.3B 5.4B 5.04B 4.63B 8.7B 602B 8.84B 59.5B 23.3B 302B 23.64B 23.12B 998B | P/E 2026 * |
30.6x | P/E 2027 * | 26.2x |
|---|---|---|---|---|---|
| Enterprise Value | 39.17B 5.82B 4.99B 4.66B 4.28B 8.04B 556B 8.17B 54.99B 21.53B 279B 21.85B 21.37B 922B | EV / Sales 2026 * |
8.29x | EV / Sales 2027 * | 6.87x |
| Free-Float |
57.83% | Yield 2026 * |
0.34% | Yield 2027 * | 0.39% |
| 1 day | -1.90% | ||
| 1 week | -4.39% | ||
| Current month | +3.59% | ||
| 1 month | +10.78% | ||
| 3 months | +30.36% | ||
| 6 months | +9.56% | ||
| Current year | +4.60% |
| 1 week | 70.62 |  | 79.79 |
| 1 month | 62.9 | | 79.99 |
| Current year | 51.51 | | 79.99 |
| 1 year | 51.51 | | 82.25 |
| 3 years | 32.1 | | 82.25 |
| 5 years | 30.53 | | 85.49 |
| 10 years | 30.53 | | 204.41 |
| Manager | Title | Age | Since |
|---|---|---|---|
Wei Chen
CEO | Chief Executive Officer | 46 | 2025-05-29 |
Qi Wang
DFI | Director of Finance/CFO | 44 | 2026-03-08 |
Ting Jia
CTO | Chief Tech/Sci/R&D Officer | - | 2026-03-08 |
| Director | Title | Age | Since |
|---|---|---|---|
Fu Ming Xu
BRD | Director/Board Member | 41 | 2025-11-16 |
Zhong Ru Gan
CHM | Chairman | 78 | 1998-06-16 |
Kai Du
BRD | Director/Board Member | 49 | 2009-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.90% | -4.39% | +11.93% | +72.15% | 6.41B | |
| +3.66% | +5.00% | +46.54% | -0.77% | 80.91B | |
| +5.49% | +20.35% | -38.64% | -38.47% | 53.62B | |
| +0.85% | -4.04% | -2.31% | +30.25% | 50.13B | |
| +0.23% | -1.80% | +13.14% | +167.24% | 47.97B | |
| +3.06% | +4.70% | +57.48% | -17.50% | 31.41B | |
| +145.07% | +146.17% | +461.57% | +41.10% | 25.14B | |
| +3.28% | +5.62% | +49.26% | +96.60% | 25.03B | |
| +1.66% | +2.83% | -3.58% | +212.40% | 21.45B | |
| +0.22% | +4.68% | +66.64% | +126.90% | 16.93B | |
| Average | +16.54% | +2.00% | +66.20% | +68.99% | 35.9B | |
| Weighted average by Cap. | +12.80% | +2.87% | +50.07% | +48.70% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.73B 702M 602M 562M 516M 970M 67.11B 986M 6.64B 2.6B 33.66B 2.64B 2.58B 111B | 5.53B 822M 705M 658M 604M 1.14B 78.55B 1.15B 7.77B 3.04B 39.4B 3.09B 3.02B 130B |
| Net income | 1.39B 207M 177M 166M 152M 286M 19.77B 290M 1.95B 765M 9.91B 777M 760M 32.78B | 1.63B 242M 207M 194M 178M 334M 23.11B 340M 2.28B 895M 11.59B 908M 888M 38.32B |
| Net Debt | -3.21B -477M -409M -382M -350M -659M -45.58B -670M -4.51B -1.77B -22.86B -1.79B -1.75B -75.59B | -4.36B -648M -556M -519M -476M -895M -61.93B -910M -6.12B -2.4B -31.06B -2.43B -2.38B -103B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-18 | CN¥71.20 | -1.90% | 11,984,320 |
| 26-08-18 | CN¥72.58 | -2.21% | 13,369,957 |
| 26-08-17 | CN¥74.22 | -1.01% | 15,841,695 |
| 26-08-14 | CN¥74.98 | -3.23% | 23,418,182 |
| 26-08-13 | CN¥77.48 | +0.36% | 30,369,486 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 603087 Stock
Select your edition
All financial news and data tailored to specific country editions
